Schizochytrium spによるDHA生産のための非ニュートン流体の混合と質量移転の強化 発酵
Xingyan Li1, Qi Hu1, Ruyu Zhang1
1College of Biotechnology and Pharmaceutical Engineering, State Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing Tech University, Nanjing 211816, China.
Bioresource technology
|September 5, 2025
まとめ
新しいプロペラデザインは,Schizochytrium spのドコサヘキサエノ酸 (DHA) 産生を著しく促進する. 発酵する この緑の戦略は,この貴重なオメガ3脂肪酸のより高い収量のために,混合と質量移転を強化します.
科学分野:
- バイオテクノロジーと生化学工学
- 微生物による発酵過程
- オメガ3脂肪酸の生産
背景:
- ドコサヘキサエノ酸 (DHA) は,Schizochytrium spの有酸素発酵によって生成される重要なオメガ3脂肪酸です.
- スキゾキトリウム (Schizochytrium sp) の発酵ブローブ 非ニュートンの流体であり,効率的な混合と質量移転に問題があります.
- バイオリアクターの設計を最適化することは,DHAの工業生産を強化するために不可欠です.
研究 の 目的:
- Schizochytrium spの非ニュートン発酵ブローンの混合と質量移転を改善する.
- DHAの生産に対する新しいプロペラ組み合わせの影響を評価する.
- 非ニュートンの流体発酵のためのバイオリアクターの構造を最適化するための基礎を提供する.
主な方法:
- 流体ダイナミクスをシミュレートするために計算式流体ダイナミクス (CFD) を利用した.
- 混合と流れパターンの実験的検証のために粒子画像速度測定法 (PIV) を採用した.
- バイオリアクターの従来のプロペラセットアップと新しいプロペラ組み合わせを比較しました.
主要な成果:
- 新しいプロペラ・コンビネーションにより,体積質量移転係数が78.67%増加し,ガス保持量は72.00%増加した.
- 新しいバイオリアクタでは,乾細胞重量,総脂質,およびDHAの収量がそれぞれ46. 99%,53. 62%,65. 50%増加した.
- 非ニュートン流体に関連する課題を克服する上で,新しい推進器設計の優れた性能を示した.
結論:
- この研究は,新しい推進器を備えた最適化されたバイオリアクターの設計が,非ニュートン流体発酵の限界を克服できることを成功裏に実証しました.
- 混合と質量移転の強化は,直接的にDHAとバイオマスの有意に高い収量につながります.
- この発見は,DHAのような高価値の脂質製品の工業的な発酵のための実行可能な技術的経路を提供します.
関連する概念動画
Microbial Fermentation
1.9K
Fermentation is a crucial anaerobic metabolic process that enables microbes to derive energy from sugar without relying on oxygen or an electron transport chain. This process is fundamental to various biological and industrial applications and is classified based on the metabolic products generated.Role of Pyruvate in FermentationPyruvate and its derivatives serve as key electron acceptors in fermentative pathways. The oxidation of NADH to regenerate NAD+ is essential for the continuation of...
1.9K
Bioreactor Design and Operational System
140
Bioreactors are engineered vessels designed to cultivate microorganisms under controlled conditions for industrial bioprocessing. They maintain sterility and allow precise regulation of pH, temperature, oxygen, and nutrient levels to optimize microbial growth and metabolite production. Bioreactors range from small laboratory units of 1 liter to industrial systems holding up to 500,000 liters, though only about 75% of their volume is actively used for fermentation. The remaining headspace...
140
Bioreactor Controls-II
64
In aerobic fermentations, oxygen is vital for microbial growth and metabolite production. Since air comprises only about 20% oxygen and the gas is poorly soluble in water—just 9 ppm at 20°C—supplying sufficient oxygen becomes a critical challenge, especially in high-demand processes like yeast growth or citric acid production. Even a fully saturated broth may offer only a few seconds of oxygen availability.To address this, sterile or scrubbed air is introduced into the...
64
Bioreactor Controls-III
55
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
55
Designing Growth Media for Bioreactors
67
Growth media provide essential nutrients that support cell growth and metabolism, thereby enhancing the yield of valuable products such as enzymes, antibiotics, and biomass. Designing an effective growth medium involves balancing all components to prevent nutrient limitations or toxic excesses, both of which can impair growth and reduce product yields.Composition of a Typical Growth MediumA typical growth medium contains carbon and nitrogen sources, salts, vitamins, trace elements, and...
67
Upstream Processing
87
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
87


